期刊文献+

阵发性睡眠性血红蛋白尿症患者CD59+与CD59-骨髓造血干细胞EPOR、TPOR表达研究

EPOR and TPOR expressions on CD34 + CD59 - and CD34 + CD59 + bone marrow cells from patients with paroxysmal nocturnal hemoglobinuria
原文传递
导出
摘要 目的研究阵发性睡眠性血红蛋白尿症(PNH)患者骨髓CD34+CD59+和CD34+CD59-细胞红细胞生成素受体(EPOR)和血小板生成素受体(TPOR)的表达。方法①应用流式细胞术检测26例PNH患者和16名正常对照者骨髓CD34+CD59-和CD34-CD59-细胞EPOR、TPOR的表达情况。②应用RT—PCR方法检测25例PNH患者和13名正常对照者骨髓单个核细胞EPOR、TPORmRNA的表达。结果@PNH患者骨髓CD34+CD59+细胞EPOR表达率[(30.67±18.30)%]明显高于CD34+CD59-细胞[(8.05±3.51)%](P〈0.01)及对照组CD34+CD59+细胞[(8.24±6.51)%](P〈0.01),但PNH患者骨髓CD34+CD59-细胞与对照组CD34-CD59+细胞EPOR表达率差异无统计学意义(P〉0.05)。②PNH患者骨髓CD34+CD59-细胞TPOR表达率[(28.15±17.75)%]明显高于CD34+CD59-细胞[(15.65±14.45)%](P〈0.05)及对照组CD34+CD59+细胞[(10.77±8.39)%](P〈0.01),但PNH患者骨髓CD34+CD59-细胞与对照组CD34+CD59+细胞TPOR表达率差异无统计学意义(P〉0.05)。(3)PNH患者骨髓单个核细胞EPORmRNA表达水平(0.41±0.37)、TPORmRNA表达水平(0.32±0.19)与对照组骨髓单个核细胞EPOR、TPORmRNA表达水平[(0.47±0.33)、(0.40±0.29)]比较,差异均无统计学意义。结论PNH患者骨髓CD34+CD59+细胞EPOR、TPOR表达明显高于CD34+CD59-细胞。 Objective To study the expressions of erythropoietin receptor (EPOR) and thrombopoietin receptor (TPOR) on CD34 + CD59- and CD34 + CD59 + bone marrow (BM) cells from patients with paroxysmal nocturnal hemoglobinuria(PNH). Methods (1)The expressions of EPOR and TPOR on CD34 +CD59 + and CD34 + CD59 - BM cells from 26 PNH patients and 16 normal controls were examined by flow cytometry (FCM). (2)The mRNA expression of the EPOR and the TPOR in BM mononuclear cells(BMMNC) from 25 PNH patients and 13 normal controls were examined by RT-PCR. Results (1)The percentage of EPOR positive cells in PNH CD34 + CD59 + BMMNC [ (30.67 ± 18.30) % ] was significantly higher than that inPNH CD34 +CD59 BMMNC [(8.05±3.51)%J (P〈0.01) and than that in control CD34 +CD59 + BMMNC [ (8.24 ± 6.51 ) % J (P 〈 0.01 ), but there was no obvious difference between the CD34 + CD59 - BMMNC in PNH and CD34 + CD59 + BMMNC in control. (2) The percentage of TPOR positive cells in PNH CD34 + CD59 + BMMNC [ (28. 15 ±17.75 ) % ] was significantly higher than that in PNH CD34 + CD59 BMMNC [(15.65±14.45)%] (P〈0.05) and than that in control CD34 +CD59 +BMMNC [(10.77± 8.39) % ] (P 〈0.01 ), but there was no obvious difference between the CD34+ CD59- BMMNC in PNH and CD34 + CD59 + BMMNC in control. (3)There was no statistic difference in EPOR mRNA and TPOR mRNA expressions in BMMNCs between PNH patients group [ (0.41 ± 0.37) and (0.32 ±0.19), respectively] and control group [ (0.47 ±0.33) and (0.40 ± 0.29), respectively]. Conclusion The expression of EPOR and TPOR of PNH patients on BM CD34+CD59 + cells are significantly higher than those on BM CD34 + CD59- cells. The difference may be due to abnormal transcription of both receptor coding genes.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2011年第8期543-547,共5页 Chinese Journal of Hematology
基金 国家自然科学基金(30971285、30971286) 国家“十一五”科技支撑项目(2008BA161B00) 高等学校博士学科点专项科研基金(200800620004) 天津市应用基础及前沿技术研究计划(08JCYBJC07800、09JCYBJC11200) 天津医科大学重点学科基金(2009xk50)
关键词 血红蛋白尿 阵发性 受体 红细胞生成素 受体 血小板生成素 造血干细胞 Hemoglobinuria, paroxysmal Receptors, erythropietin Receptors, thrombopietic Hematopoietic stem cell
  • 相关文献

参考文献3

二级参考文献36

  • 1Bao H, Jacobs-Helber SM, Lawson AE, et al. Protein kinase B (cAkt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (
  • 2Morishita E, Masuda S, Nagao M, et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortica1 neurons, and erythropoietin prevents in vitro glutamate- induced neuronal death.Neuroscience, 1997; 76:105 - 116
  • 3Yang M, Li K, Chui CM, et al. Expression of interleukin (IL) 1type Ⅰ and type Ⅱ receptors in megakaryocytic cells and enhancing effects of IL-1beta on megakaryocytopoiesis and NF-E2 expression.Br J Haematol. 2000; 111: 371 - 380
  • 4Kaushansky K. Thrombopoietin. N Engl J Med, 1998; 339:746 -754
  • 5Juul SE, Anderson DK, Li Y, et al. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res, 1998; 43:40-49
  • 6Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA, 1998; 95:4635-4640
  • 7Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA. 2000; 97:10526- 10531
  • 8Dawson TM. Preconditioning-mediated neuroprotection through erythropoietin? Lancet, 2002; 359 (9301): 96 - 97
  • 9Yang M, Li K, Yuen PMP, et al. Expression of 5-HT 2A, 2B and 2C receptors and MAP2, GFAP and Tau on human megakaryocytes and megakaryocytic cell lines. Blood, 2001, 98 Suppl; 48b
  • 10Li K, Yang M, Yuen PM, et al. Thrombospondin-1 induces apoptosis in primary leukemia and cell lines mediated by CD36 and Caspase-3. Int J Mol Med, 2003; 12:995- 1001

共引文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部